MedinCell Will Publish Its Half-year Results (April-September 2023) on 19 December 2023

Regulatory News:

MedinCell (Paris:MEDCL):

Due to organizational imperatives, the publication of half-year results for the period ended 30 September 2023, initially scheduled for 6 December, has been postponed to 19 December 2023.

About MedinCell

MedinCell is a clinical- and commercial-stage biopharmaceutical company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine already known and used active ingredients with our proprietary BEPO^® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY" (BEPO technology is licensed to Teva under the name SteadyTeq").

We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, MedinCell currently employs more than 140 people representing more than 25 different nationalities.

UZEDY" and SteadyTeq" are trademarks of Teva Pharmaceuticals

www.medincell.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20231120204190/en/

David Heuzé - Head of Communications
david.heuze@medincell.com / +33 (0)6 83 25 21 86

Media Relations
Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94

Investor Relations France
Louis-Victor Delouvrier/Alban Dufumier
medincell@newcap.eu / +33 (0)1 44 71 94 94

Head of US Financial Strategy & IR
Grace Kim
grace.kim@medincell.com / +1 (646) 991-4023